MCID: INF038
MIFTS: 71

Influenza

Categories: Respiratory diseases, Infectious diseases, Genetic diseases

Aliases & Classifications for Influenza

Summaries for Influenza

MedlinePlus : 41 flu is a respiratory infection caused by a number of viruses. the viruses pass through the air and enter your body through your nose or mouth. between 5% and 20% of people in the u.s. get the flu each year. the flu can be serious or even deadly for elderly people, newborn babies, and people with certain chronic illnesses. symptoms of the flu come on suddenly and are worse than those of the common cold. they may include body or muscle aches chills cough fever headache sore throat is it a cold or the flu? colds rarely cause a fever or headaches. flu almost never causes an upset stomach. and "stomach flu" isn't really flu at all, but gastroenteritis. most people with the flu recover on their own without medical care. people with mild cases of the flu should stay home and avoid contact with others, except to get medical care. if you get the flu, your health care provider may prescribe medicine to help your body fight the infection and lessen symptoms. the main way to keep from getting the flu is to get a yearly flu vaccine. good hygiene, including hand washing, can also help. nih: national institute of allergy and infectious diseases

MalaCards based summary : Influenza, also known as flu, is related to hepatitis c virus and avian influenza, and has symptoms including coughing, fever and pruritus. An important gene associated with Influenza is IVNS1ABP (Influenza Virus NS1A Binding Protein), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Tequin and Oseltamivir have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and t cells, and related phenotypes are Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers and Decreased influenza A H1N1 (A/WSN/33) virus numbers

CDC : 3 The best way to prevent seasonal flu is to get vaccinated every year.

Disease Ontology : 12 A viral infectious disease that results_in infection, located in respiratory tract, has material basis in Influenzavirus A, has material basis in Influenzavirus B, or has material basis in Influenzavirus C, which are transmitted_by droplet spread of oronasal secretions during coughing, sneezing, or talking from an infected person. It is a highly contagious disease that affects birds and mammals and has symptom chills, has symptom fever, has symptom sore throat, has symptom runny nose, has symptom muscle pains, has symptom severe headache, has symptom cough, and has symptom weakness.

Wikipedia : 72 Influenza, commonly known as \"the flu\", is an infectious disease caused by an influenza virus.... more...

Related Diseases for Influenza

Diseases in the Influenza family:

Influenza, Severe

Diseases related to Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 454)
id Related Disease Score Top Affiliating Genes
1 hepatitis c virus 29.5 DDX58 IFNG IRF7 RSAD2
2 avian influenza 12.5
3 swine influenza 12.4
4 haemophilus influenzae 12.3
5 influenza, severe 11.8
6 viral pneumonia 11.3
7 haemophilus meningitis 11.2
8 acute necrotizing encephalopathy 11.2
9 epiglottitis 11.1
10 common cold 11.0
11 lung disease 11.0
12 croup 11.0
13 acute diarrhea 11.0
14 encephalopathy, acute, infection-induced, 4 10.8
15 specific antibody deficiency 10.8
16 spastic paraplegia 15, autosomal recessive 10.8 IFNA1 ISG15 MX1
17 human monocytic ehrlichiosis 10.7 DDX58 HLA-DQB1 RSAD2
18 immunodeficiency 39 10.7
19 c3 deficiency 10.7
20 pontiac fever 10.7
21 selective igm deficiency disease 10.7
22 haverhill fever 10.7
23 gastroenteritis 10.7
24 white matter hypoplasia-corpus callosum agenesis-intellectual disability syndrome 10.7
25 orofaciodigital syndrome 10.7 DDX58 FURIN IRF7
26 mosaic trisomy 1 10.6 HLA-DQB1 IFNG
27 congenital nystagmus 10.6 DDX58 IFITM3 IFNA1 RSAD2
28 periodic paralysis with later-onset distal motor neuropathy 10.6 HLA-DQB1 IFNG
29 pulmonary tuberculosis 10.5 IFNA1 IFNG TMPRSS2
30 bacterial gastritis 10.5 IFNA1 IFNG MX1
31 advanced sleep phase syndrome, familial, 1 10.5 HLA-DQB1 IFNA1 IFNG MX1
32 neonatal jaundice 10.5 IFNA1 IFNG MX1
33 bronchitis 10.5
34 diabetes mellitus, insulin-dependent, 22 10.5 DDX58 IFITM3 IFNA1 MX1 RSAD2
35 bronchopneumonia 10.5
36 gerstmann syndrome 10.4 IFNG TRIM25
37 eczematous dermatitis of eyelid 10.4 DDX58 IFNA1 IFNG IRF7
38 pneumonia 10.4
39 vaginal mullerian papilloma 10.4 IFITM3 MX1
40 anaerobic pneumonia 10.3
41 carotid artery dissection 10.3 DDX58 IFNA1 IFNG IRF7 ISG15 MX1
42 upper lip cancer 10.3 DDX58 IFNA1 IFNG
43 tetanus 10.3
44 ornithosis 10.2
45 pertussis 10.2
46 diphtheria 10.2
47 newcastle disease 10.1
48 hepatitis 10.1
49 meningitis 10.1
50 hepatitis b 10.1

Graphical network of the top 20 diseases related to Influenza:



Diseases related to Influenza

Symptoms & Phenotypes for Influenza

UMLS symptoms related to Influenza:


coughing, fever, pruritus, snoring, influenza-like symptoms, fever, catarrhal, acute, symptoms

GenomeRNAi Phenotypes related to Influenza according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 9.13 ISG15 NXF1 XPO1
2 Decreased influenza A H1N1 (A/WSN/33) virus numbers GR00195-A-2 8.8 ISG15 NXF1 XPO1

Drugs & Therapeutics for Influenza

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Tequin 17 Bristol-Myers Squibb December, 1999

Drugs for Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 801)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4,Phase 3,Phase 2,Phase 1 204255-11-8, 196618-13-0 65028
2
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 26787-78-0 33613 2171
3
4-Aminopyridine Approved Phase 4,Phase 2 504-24-5 1727
4
Formaldehyde Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-00-0 712
5
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
6
Ephedrine Approved Phase 4,Phase 3,Phase 1 299-42-3 9294
7
Oxymetazoline Approved Phase 4,Phase 3,Phase 1 1491-59-4 4636
8
Phenylephrine Approved Phase 4,Phase 3,Phase 1 59-42-7 6041
9
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1 90-82-4 7028
10
Guaifenesin Approved, Vet_approved Phase 4,Phase 3 93-14-1 3516
11
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1 75614-87-8, 51-45-6 774
12
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
13
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
14
Calcium Carbonate Approved Phase 4,Phase 3,Phase 1 471-34-1
15
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
16
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
17
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 55-98-1 2478
18
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
19
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
20
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
22
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
23
Fluconazole Approved Phase 4,Phase 3,Phase 2 86386-73-4 3365
24
Coal tar Approved Phase 4 8007-45-2
25
Peramivir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 229614-55-5, 330600-85-6 151164
26
Acenocoumarol Approved Phase 4 152-72-7 9052 54676537
27
Zanamivir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 139110-80-8 60855
28
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
29
Certolizumab pegol Approved Phase 4 428863-50-7
30
Adalimumab Approved Phase 4,Phase 2 331731-18-1 16219006
31
Ibuprofen Approved Phase 4,Phase 3,Phase 1 15687-27-1 3672
32
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
33
Probenecid Approved Phase 4,Phase 1 57-66-9 4911
34
Dextromethorphan Approved Phase 4,Phase 3 125-71-3 5360696 5362449
35
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 145258-61-3 6438354
36
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
37
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
38
Salmon Calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
39
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 1 50-28-2 5757
40
Ethinyl Estradiol Approved Phase 4,Phase 1 57-63-6 5991
41
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
42
Norgestimate Approved Phase 4,Phase 1 35189-28-7 6540478
43
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
44
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
45
Remifentanil Approved Phase 4 132875-61-7 60815
46
Amantadine Approved Phase 4,Phase 2,Phase 1 768-94-5 2130
47
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
48
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
49
Sulfadiazine Approved, Vet_approved Phase 4 68-35-9 5215
50
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812

Interventional clinical trials:

(show top 50) (show all 3299)

id Name Status NCT ID Phase Drugs
1 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
2 Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff. Unknown status NCT01063608 Phase 4
3 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
4 A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold Unknown status NCT01651663 Phase 4 Arbidol (Umifenovir);Arbidol (Umifenovir)
5 Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults Unknown status NCT01967368 Phase 4 Intanza;Vaxigrip
6 High Dose Influenza Vaccine in Nursing Home Unknown status NCT01720277 Phase 4
7 Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults Unknown status NCT01811823 Phase 4
8 Influenza Vaccination in Patients With Scleroderma Unknown status NCT01002508 Phase 4
9 Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines Unknown status NCT01119157 Phase 4
10 Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine,Formulation 2011-2012, in Dialysis Patients Unknown status NCT01512056 Phase 4 AdimFlu-S
11 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
12 Immunogenicity of Influenza Vaccines in HIV-infected Persons in Thailand Unknown status NCT01538940 Phase 4
13 A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes Unknown status NCT01053377 Phase 4 Tamiflu (verum);Tamiflu placebo
14 Efficacy of Sambucol in the Treatment of Influenza Unknown status NCT00375115 Phase 4 Sambucol
15 Chinese Medicinal Herbs Treatment on Novel Influenza A (H1N1)Pneumonia: Multi-centre, Prospective, Randomized Controlled Study Unknown status NCT00936013 Phase 4 oseltamivir;oseltamivir and chinese medicinal herbs
16 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4 Vitamin (vitamin A 15 mg,C 500 mg, E 400IU);Placebo (digestive tablet)
17 Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease Unknown status NCT02563184 Phase 4
18 Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years Unknown status NCT01289535 Phase 4
19 Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine Unknown status NCT01980836 Phase 4
20 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
21 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
22 Comparing Treatment Efficacy With HD/MD Flu Plus Sal in Chronic Obstructive Pulmonary Disease (COPD) Patients Unknown status NCT01131806 Phase 4 fluticasone/ salmeterol 125/25 mcg/puff;fluticasone/ salmeterol 250/25 mcg/puff
23 Middle Meatal Bacteriology During Acute Respiratory Infection in Children Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
24 Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine Unknown status NCT00877357 Phase 4
25 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Unknown status NCT02259361 Phase 4 Sustained-release oral dalfampridine;Placebo
26 Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine Completed NCT02819115 Phase 4
27 Influenza Vaccination for Parents and Other Caregivers in the Pediatric Medical Home Completed NCT00812110 Phase 4 Influenzae vaccine
28 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
29 Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting Completed NCT01654224 Phase 4
30 Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation. Completed NCT00390884 Phase 4
31 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines Completed NCT01004653 Phase 4
32 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine Completed NCT02222870 Phase 4
33 Influenza Vaccine in HIV Infected Children Completed NCT00883012 Phase 4
34 A Study to Evaluate the Safety and Immune Responses to Fluzone® Vaccination Completed NCT00835926 Phase 4
35 Self-Administered Nasal Influenza Feasibility Study Completed NCT01933048 Phase 4 FluMist
36 The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine Completed NCT01736709 Phase 4
37 Phase IV Trial to Collect Safety Data and Sera for Immunogenicity Testing in Healthy Children Given Fluzone® Vaccine Completed NCT00561002 Phase 4
38 Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season Completed NCT02473510 Phase 4
39 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
40 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation) Completed NCT01691326 Phase 4
41 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season Completed NCT02743117 Phase 4
42 Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations Completed NCT02908269 Phase 4
43 Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among Adults Completed NCT01430819 Phase 4
44 Maternal Flu Vaccine Trial in Bamako, Mali Completed NCT01430689 Phase 4
45 Inactivated Influenza Via Jet Injection Completed NCT02290691 Phase 4
46 A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years Completed NCT02212106 Phase 4
47 Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine Completed NCT00258817 Phase 4
48 Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military Completed NCT02640989 Phase 4
49 Hutterite Influenza Prevention Study Completed NCT00877396 Phase 4
50 Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine Completed NCT01946425 Phase 4

Search NIH Clinical Center for Influenza

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: influenza, human

Genetic Tests for Influenza

Genetic tests related to Influenza:

id Genetic test Affiliating Genes
1 Influenza 29

Anatomical Context for Influenza

MalaCards organs/tissues related to Influenza:

39
Testes, Lung, T Cells, Brain, Bone, Heart, Breast

Publications for Influenza

Articles related to Influenza:

(show top 50) (show all 4508)
id Title Authors Year
1
H9N2 avian influenza virus enhances the immune responses of BMDCs by down-regulating miR29c. ( 28063705 )
2017
2
Bacteremic renal stone-associated urinary tract infection caused by nontypable Haemophilus influenzae: A rare invasive disease in an immunocompetent patient. ( 27920983 )
2017
3
Successful Treatment of Influenza-Associated Acute Necrotizing Encephalitis in an Adult Using High-Dose Oseltamivir and Methylprednisolone: Case Report and Literature Review. ( 28852683 )
2017
4
Possible explanations for why some countries were harder hit by the pandemic influenza virus in 2009 - a global mortality impact modeling study. ( 28946870 )
2017
5
Nontypeable Haemophilus influenzae (NTHi) directly interfere with the regulation of E-cadherin in lung epithelial cells. ( 28802586 )
2017
6
Henoch-SchAPnlein Purpura and Influenza Vaccine. ( 28065339 )
2017
7
Transmission and immunopathology of the avian influenza virus A/Anhui/1/2013 (H7N9) human isolate in three commonly commercialized avian species. ( 28905526 )
2017
8
An M2-V27A channel blocker demonstrates potent inA vitro and inA vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses. ( 28087313 )
2017
9
Harnessing Local Immunity for an Effective Universal Swine Influenza Vaccine. ( 28475122 )
2017
10
Haemophilus influenzae biofilms in primary ciliary dyskinesia: a moving story. ( 28890441 )
2017
11
Secondary organizing pneumonia following viral pneumonia caused by severe influenza B: a case report and literature reviews. ( 28810835 )
2017
12
Extracorporeal Life Support for severe respiratory failure with special reference to the influenza H1N1 pandemic. ( 28066903 )
2017
13
Genetic analysis of human and swine influenza A viruses isolated in Northern Italy during 2010-2015. ( 28791803 )
2017
14
Novel reassortant clade 2.3.4.4 avian influenza A (H5N8) virus in a grey heron in South Korea in 2017. ( 28900762 )
2017
15
Interstitial Pneumonia Associated with the Influenza Vaccine: A Report of Two Cases. ( 28090052 )
2017
16
Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins. ( 28079473 )
2017
17
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. ( 28077641 )
2017
18
Risk of Human Infections With Highly Pathogenic H5N2 and Low Pathogenic H7N1 Avian Influenza Strains During Outbreaks in Ostriches in South Africa. ( 28934458 )
2017
19
MicroRNA-146a induction during influenza H3N2 virus infection targets and regulates TRAF6 levels in human nasal epithelial cells (hNECs). ( 28131813 )
2017
20
Host Cellular Protein TRAPPC6AI9 Interacts with Influenza A Virus M2 Protein and Regulates Viral Propagation by Modulating M2 Trafficking. ( 27795429 )
2017
21
Pathogenesis, Transmissibility, and Tropism of a Highly Pathogenic Avian Influenza A(H7N7) Virus Associated With Human Conjunctivitis in Italy, 2013. ( 28934452 )
2017
22
Very Severe Secondary Sclerosing Cholangitis as a Sequela of Influenza. ( 28683859 )
2017
23
Hemophagocytic lymphohistiocytosis following influenza vaccination in a patient with aplastic anemia undergoing allogeneic bone marrow stem cell transplantation. ( 28054244 )
2017
24
Single PA mutation as a high yield determinant of avian influenza vaccines. ( 28084423 )
2017
25
Estimating Risks of Inapparent Avian Exposure for Human Infection: Avian Influenza Virus A (H7N9) in Zhejiang Province, China. ( 28054599 )
2017
26
Double Plant Homeodomain Fingers 2 (DPF2) Promotes the Immune Escape of Influenza Virus by Suppressing Beta Interferon Production. ( 28404846 )
2017
27
Pre-mRNA Processing Factor Prp18 Is a Stimulatory Factor of Influenza Virus RNA Synthesis and Possesses Nucleoprotein Chaperone Activity. ( 27852861 )
2017
28
Haemophilus influenzae Type b Invasive Disease in Amish Children, Missouri, USA, 2014. ( 27983486 )
2017
29
Widespread Virus Replication in Alveoli Drives Acute Respiratory Distress Syndrome in Aerosolized H5N1 Influenza Infection of Macaques. ( 28062701 )
2017
30
Blood-Brain Barrier in a Haemophilus influenzae Type a In Vitro Infection: Role of Adenosine Receptors A2A and A2B. ( 28921456 )
2017
31
Genetic characterisation of novel, highly pathogenic avian influenza (HPAI) H5N6 viruses isolated in birds, South Korea, November 2016. ( 28079520 )
2017
32
Alveolar Macrophages Prevent Lethal Influenza Pneumonia By Inhibiting Infection Of Type-1 Alveolar Epithelial Cells. ( 28085958 )
2017
33
Beta-lactam resistance among Haemophilus influenzae isolates in Poland. ( 28818575 )
2017
34
Five distinct reassortants of H5N6 highly pathogenic avian influenza A viruses affected Japan during the winter of 2016-2017. ( 28892736 )
2017
35
Antibody Affinity Against 2009 A/H1N1 Influenza and Pandemrix Vaccine Nucleoproteins Differs Between Childhood Narcolepsy Patients and Controls. ( 28796576 )
2017
36
Influenza vaccination and risk of respiratory failure in patients with chronic obstructive pulmonary disease: A nationwide population-based case-cohort study. ( 28927683 )
2017
37
Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication. ( 28953980 )
2017
38
EVALUATION OF A COMMERCIAL COMPETITIVE ENZYME-LINKED IMMUNOSORBENT ASSAY FOR DETECTION OF AVIAN INFLUENZA VIRUS SUBTYPE H5 ANTIBODIES IN ZOO BIRDS. ( 28920801 )
2017
39
Immune efficacy of an adenoviral vector-based swine influenza vaccine against antigenically distinct H1N1 strains in mice. ( 28941982 )
2017
40
Characterization of Monoclonal Antibodies against HA Protein of H1N1 Swine Influenza Virus and Protective Efficacy against H1 Viruses in Mice. ( 28786930 )
2017
41
Immunogenicity of Nontypeable Haemophilus influenzae Outer Membrane Vesicles and Protective Ability in the Chinchilla Model of Otitis Media. ( 28768669 )
2017
42
Genome Sequence of an Unusual Reassortant H1N1 Swine Influenza Virus Isolated from a Pig in Russia, 2016. ( 28883131 )
2017
43
Feral Swine in the United States Have Been Exposed to both Avian and Swine Influenza A Viruses. ( 28733290 )
2017
44
Influence of microclimate conditions on the cumulative exposure of nursery pigs to swine influenza A viruses. ( 28940764 )
2017
45
Antimicrobial susceptibility of Haemophilus influenzae strains isolated from the urethra of men with acute urethritis and/or epididymitis. ( 28619239 )
2017
46
Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy. ( 28077631 )
2017
47
Haemophilus influenzae Serotype f Epiglottitis: A Case Report and Review. ( 28028010 )
2017
48
Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. ( 28479019 )
2017
49
Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study. ( 28866290 )
2017
50
Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. ( 28847694 )
2017

Variations for Influenza

Expression for Influenza

LifeMap Discovery
Genes differentially expressed in tissues of Influenza patients vs. healthy controls: 35 (show all 45)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 6.13 0.000
2 OTOF otoferlin Blood + 5.57 0.000
3 KCTD14 potassium channel tetramerization domain containing 14 Blood + 5.45 0.000
4 HESX1 HESX homeobox 1 Blood + 4.33 0.000
5 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial Blood + 4.32 0.000
6 CCNA1 cyclin A1 Blood + 4.26 0.000
7 METTL7B methyltransferase like 7B Blood + 4.12 0.000
8 C1QC complement component 1, q subcomponent, C chain Blood + 4.11 0.000
9 OLFM4 olfactomedin 4 Blood + 3.99 0.000
10 SIGLEC1 sialic acid binding Ig-like lectin 1, sialoadhesin Blood + 3.98 0.000
11 OLFM1 olfactomedin 1 Blood - 3.92 0.000
12 RSAD2 radical S-adenosyl methionine domain containing 2 Blood + 3.86 0.000
13 GPR42 G protein-coupled receptor 42 (gene/pseudogene) Blood + 3.85 0.000
14 RNASE1 ribonuclease, RNase A family, 1 (pancreatic) Blood + 3.83 0.000
15 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Blood + 3.80 0.000
16 KCNE1 potassium channel, voltage gated subfamily E regulatory beta subunit 1 Blood + 3.73 0.000
17 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Blood + 3.70 0.000
18 TMEM119 transmembrane protein 119 Blood + 3.66 0.000
19 DNAAF1 dynein, axonemal, assembly factor 1 Blood + 3.54 0.000
20 HP haptoglobin Blood + 3.46 0.000
21 PRSS33 protease, serine, 33 Blood - 3.42 0.000
22 IFI44L interferon-induced protein 44-like Blood + 3.42 0.000
23 PPARG peroxisome proliferator-activated receptor gamma Blood + 3.38 0.000
24 PID1 phosphotyrosine interaction domain containing 1 Blood - 3.37 0.000
25 SLC26A8 solute carrier family 26 (anion exchanger), member 8 Blood + 3.37 0.000
26 IFITM4P interferon induced transmembrane protein 4 pseudogene Blood + 3.31 0.000
27 CNTNAP2 contactin associated protein-like 2 Blood - 3.30 0.000
28 PTGDR2 prostaglandin D2 receptor 2 Blood - 3.28 0.000
29 IFIT1 interferon-induced protein with tetratricopeptide repeats 1